Gov. Eric Holcomb on Wednesday defended his signing of a near-total abortion ban this month and brushed off fears of business and talent attraction consequences in the wake of ominous statements from major homegrown employers.
Read MoreEli Lilly and Co. says it will donate an unspecified amount of its COVID-19 therapies to low and lower-middle-income countries most heavily affected by the pandemic.
Read MoreWhen Indianapolis-based Eli Lilly and Co., received Emergency Use Authorization from the US Food and Drug Administration for its COVID-19 therapy bamlanivimab, it marked a significant step in the fight against COVID-19.
Read MoreBy DAN MCGOWAN Writer/Reporter, Inside Indiana Business A potential rheumatoid arthritis treatment being co-developed by Indianapolis-based Eli Lilly and Co. and Incyte Corp. continues to return positive results in late-stage testing. In a recent phase-three global study, Lilly says baricitinib met its primary endpoint. The results have been published in … Read More
By ANDY OBER Assistant Managing Editor InsideIndianaBusiness INDIANAPOLIS — The U.S. Food and Drug Administration has approved a type 2 diabetes treatment from Indianapolis-based Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc. Synjardy was also approved earlier this year by the European Medicines Agency. Lilly says Synjardy is the … Read More
Eli Lilly and Company (NYSE: LLY) yesterday announced that it has completed the acquisition of Novartis Animal Health, which will further position Lilly’s Elanco as a global leader in the animal health industry. The transaction, first announced on April 22, has received clearance under the Hart-Scott-Rodino Antitrust Improvements … Read More
Eli Lilly and Company (NYSE: LLY) has received its third US Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). Specifically, CYRAMZA is now also indicated in combination with docetaxel, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients … Read More
Eli Lilly and Company (NYSE: LLY) and AstraZeneca yesterday announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease. AZD3293, also known as LY3314814, has been shown … Read More
